WAM
OREX

Wealthspire Advisors (Maryland)’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-50
Closed – – 2652
2017
Q2 		$0 Hold
50
– – ﹤0.01% 2388
2017
Q1 		$0 Hold
50
– – ﹤0.01% 2118
2016
Q4 		$0 Hold
50
– – ﹤0.01% 1941
2016
Q3 		$0 Buy
+50
New +$189 ﹤0.01% 1899
2016
Q2 		– Sell
-51
Closed – – 1936
2016
Q1 		$0 Hold
51
– – ﹤0.01% 1985
2015
Q4 		$1K Buy
+51
New +$1.22K ﹤0.01% 1712

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s OREX Position: Q3 2017 in Review

Wealthspire Advisors (Maryland) sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 50 shares.

Wealthspire Advisors (Maryland) first reported a position in OREX in Q4 2015 and held it in 6 quarters. The position peaked at $1K in Q4 2015. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

  • Wealthspire Advisors (Maryland) reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 50 Orexigen Therapeutics, Inc. shares in Q3 2017.
  • Wealthspire Advisors (Maryland) first reported a position in Orexigen Therapeutics, Inc. in Q4 2015 and held it in 6 quarters.
  • Wealthspire Advisors (Maryland)'s Orexigen Therapeutics, Inc. position peaked at $1K in Q4 2015.
  • 42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q3 2017, filed 8 Nov 2017.